A
weekly e-journal by Art Epstein, OD, FAAO
Off the Cuff: Wet or Dry – What Are You Putting in Your Patient’s Eye?
I just completed presenting a webinar with good friends and esteemed colleagues Paul Karpecki, Doug Devries, Damon Dierker and Ahmad Fahmy. Sponsored by Bio-Tissue, “Redefining the Standard of Care: A Consensus Guideline” revisited a number of anterior segment disorders from the perspective of improving current standards of care by integrating new research and clinical advances.
|
|||||
A Randomized Clinical Trial of Multifocal Contact Lenses and Contact Lens Discomfort | ||||
This randomized, participant-masked, crossover clinical trial fitted 84 uncomfortable soft contact lens wearers (30 to 40 years old) with single vision and multifocal contact lenses to determine how multifocal contact lenses affected contact lens discomfort. Contact lens discomfort was assessed using the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8). No difference was found between multifocal and single vision survey scores. An interaction was found between lens type and age group. CLDEQ-8 scores with the single vision lens were less symptomatic than multifocal scores in participants <35 years old. Single vision and multifocal scores for the older age group were not different. Subjectively, those in the <35-year-old group preferred the single vision lens for intermediate, distance and overall vision. In the ≥35-year-old group, no lens was significantly preferred for vision. |
||||
SOURCE: Rueff EM, Jones-Jordan LA, Bailey MD. A randomised clinical trial of multifocal contact lenses and contact lens discomfort. Ophthalmic Physiol Opt. 2020; Nov 18. [Epub ahead of print.] |
Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: a Case Report | ||||
Neurotrophic keratitis (NK) is one of the most challenging ocular conditions to treat, and it can represent a devastating complication of acoustic neuroma surgery due to the profound corneal anesthesia and concomitant exposure keratopathy caused by seventh nerve palsy. In such cases, cornea surgery should be considered with extreme caution due to the high risk of devastating complications. The purpose of this study was to report the efficacy of a novel human recombinant nerve growth factor (rhNGF)-based ophthalmic treatment in a functionally monocular patient with a recurrence of severe NK on a corneal graft.
|
||||
SOURCE: Pocobelli A, Komaiha C, De Carlo L, et al. Role of topical cenegermin in management of a cornea transplant in a functionally monocular patient with neurotrophic keratitis and facial nerve palsy: a case report. Int Med Case Rep J. 2020; Nov 11;13:617-21. |
Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity | ||||
Retinopathy of prematurity (ROP) is one of the many significant consequences of premature birth, and remains one of the leading causes of visual impairment in infants. Originally, cryotherapy was used to prevent the complications of vitreous hemorrhage and retinal detachment. Subsequently, the authors wrote, laser photocoagulation, which is at least as effective and possibly safer than cryoretinopexy, was adopted as the primary treatment for type 1 ROP (stage 2 or 3 disease in zone II with plus disease, or any stage disease in zone I with plus disease, or stage 3 disease in zone I without plus disease). Laser therapy has been shown to be effective, and has a degree of permanence that is yet to be matched by alternative treatments, but can be associated with significant ocular side effects such as myopia. Treatment of type 1 ROP with anti-vascular endothelial growth factor (VEGF) agents seems to have fewer ocular side effects than laser ablation of the retina, particularly if used to treat type 1 ROP in zone I, the authors wrote. However, ROP recurrence is a real threat after anti-VEGF therapy, and long-term systemic side effects of this therapy remain under evaluation. This review focused on the ophthalmic and systemic benefits and risks of anti-VEGF therapies for ROP compared with retinal photocoagulation. |
||||
SOURCE: Seery CW, Betesh S, Guo S, et al. Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2020; Nov 1;57(6):351-62. |
News & Notes | ||||||||
Bausch Health: Investigational In Vitro Data Indicates Complete Inactivation of SARS-CoV-2 with LUMIFY And BESIVANCE |
||||||||
Coburn Introduces Agility Autodeblocker Coburn Technologies introduced a new product category to its surfacing line of products with an automatic lens deblocker, the Agility Autodeblocker. Developed for large labs seeking speed and efficiency, the system is capable of deblocking more than 200 lenses per hour. Both lenses are automatically removed from a job tray, placed onto the appropriate deblocking rings and then deblocked simultaneously using a mechanical action. Rather than using powerful water jets that displace alloy, cause alloy waste and produce contaminated water waste, Agility separates the lens from the block, without water, in one mechanical action. Contact the company to learn more. |
||||||||
Thyroid Eye Disease Awareness Week Launches November 16 marked the start of the first Thyroid Eye Disease (TED) Awareness Week, established through a collaboration between Horizon Therapeutics and advocacy organizations including the American Autoimmune Related Diseases Association (AARDA), the Alliance for Eye and Vision Research (AEVR), the Graves’ Disease and Thyroid Foundation (GDATF) and Prevent Blindness. Each organization planned a variety of activities throughout the week. Learn more. |
||||||||
Regener-Eyes Pledges Support to Prevent Blindness Regener-Eyes announced that Regener-Eyes is launching a campaign to support the ongoing efforts of Prevent Blindness. Now through January 15, 2021, Regener-Eyes will donate $1 to Prevent Blindness for each purchase of either Regener-Eyes LITE or Regener-Eyes Professional Strength eye drops. Regener-Eyes is a sterile biologic eye drop made of anti-inflammatory cytokines and growth factors, shown to reduce inflammation and help stimulate the ocular surface to heal, repair and regenerate. Read more. |
||||||||
|
||||||||
|
|
Optometric Physician™ (OP) newsletter is owned and published by Dr. Arthur Epstein. It is distributed by the Review Group, a Division of Jobson Medical Information LLC (JMI), 19 Campus Boulevard, Newtown Square, PA 19073. HOW TO ADVERTISE |